PT  - JOURNAL ARTICLE
AU  - Diego Garcia-Borreguero
AU  - Per Odin
AU  - Carolina Serrano
TI  - Restless legs syndrome and PD
AID  - 10.1212/WNL.61.6_suppl_3.S49
DP  - 2003 Sep 23
TA  - Neurology
PG  - S49--S55
VI  - 61
IP  - 6 suppl 3
4099  - http://n.neurology.org/content/61/6_suppl_3/S49.short
4100  - http://n.neurology.org/content/61/6_suppl_3/S49.full
SO  - Neurology2003 Sep 23; 61
AB  - Restless legs syndrome (RLS) is a common neurologic disorder whose prevalence has been estimated at 4 to 10% of the general population. Although its pathophysiology remains unknown, dopaminergic mechanisms are believed to play a central role. Furthermore, dopaminergic drugs have shown therapeutic efficacy in various large-scale therapeutic trials, and dopamine agonists now represent the first line of treatment. Several studies performed over the past years have suggested an association between RLS and Parkinson’s disease (PD). However, the evidence is still limited and large controlled studies are needed to show the prevalence rates of PD in RLS patients versus controls. Furthermore, in contrast to PD, some brain imaging studies have revealed a mild striatal dysfunction in RLS. Preliminary neuropathologic evidence also suggests that the dopaminergic dysfunction does not involve neuronal degeneration at that level. Therefore, neuronal degeneration in other dopaminergic pathways than the nigrostriatal might be relevant in the pathogenesis of RLS in PD.